Kanada - angličtina - Health Canada

pro doc limitee - perindopril erbumine - tablet - 4mg - perindopril erbumine 4mg - angiotensin-converting enzyme inhibitors

Kanada - angličtina - Health Canada

pro doc limitee - perindopril erbumine - tablet - 8mg - perindopril erbumine 8mg - angiotensin-converting enzyme inhibitors

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - perindopril erbumine -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - perindopril erbumine -

Kanada - angličtina - Health Canada

mylan pharmaceuticals ulc - perindopril erbumine - tablet - 2mg - perindopril erbumine 2mg - angiotensin-converting enzyme inhibitors

Kanada - angličtina - Health Canada

mylan pharmaceuticals ulc - perindopril erbumine - tablet - 4mg - perindopril erbumine 4mg - angiotensin-converting enzyme inhibitors

Kanada - angličtina - Health Canada

mylan pharmaceuticals ulc - perindopril erbumine - tablet - 8mg - perindopril erbumine 8mg - angiotensin-converting enzyme inhibitors

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - indapamide hemihydrate,perindopril erbumine -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; silica dimethyl silylate; microcrystalline cellulose; magnesium stearate - indopril 8 is indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that indopril 8 be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; silica dimethyl silylate; lactose monohydrate - indopril 4 is indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that indopril 4 be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.